The Uzbek company has prepared a separate line for the production of the Anhui Zhifei Longkom Biopharmaceutical vaccine, which has already been audited by Chinese experts, TASS news agency reported.

It is expected that in the near future a series will be developed for the validation of the vaccine, after which its production will be authorized.

The drug to be developed in Uzbekistan will be obtained by producing the recombining protein NCP-RBD from SARS-CoV-2 coronavirus.

pgh/lcp